Effect of a Psychological Intervention on Antiretroviral Therapy and Mental Health Outcomes in HIV-positive Adults in Zimbabwe

Sponsor
University of Bern (Other)
Overall Status
Completed
CT.gov ID
NCT03704805
Collaborator
SolidarMed (Other)
480
1
2
28.1
17.1

Study Details

Study Description

Brief Summary

The aim of the study is to examine the effect of a psychological intervention on antiretroviral therapy outcomes and symptoms of common mental health disorders among adults living with HIV and common mental disorders in rural Zimbabwe.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Friendship bench intervention
  • Other: Enhanced Standard of Care
N/A

Detailed Description

Common mental disorders are highly prevalent among people living with HIV. Left untreated, common mental disorders cause substantial disability and undermine individuals' ability to adhere to antiretroviral therapy, leading to poor antiretroviral therapy outcomes.

A recent cluster-randomized controlled trial from Harare, Zimbabwe showed that the friendship bench intervention (i.e. six sessions of problem-solving therapy delivered by lay health workers followed by a peer support group) effectively reduced symptoms of common mental disorders, but the effect of the intervention on antiretroviral therapy outcomes and its effectiveness in the rural setting has not been studied.

To examine the effect of the friendship bench intervention on antiretroviral therapy outcomes and symptoms of common mental disorders among adults living with HIV and common mental disorders in rural Zimbabwe, a cluster-randomized trial is conducted.

Study Design

Study Type:
Interventional
Actual Enrollment :
480 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Cluster-randomized, controlled, two-arm multicenter, superiority trialCluster-randomized, controlled, two-arm multicenter, superiority trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effect of a Psychological Intervention on Antiretroviral Therapy Outcomes and Symptoms of Common Mental Disorders in HIV-positive Adults in Rural Zimbabwe
Actual Study Start Date :
Oct 5, 2018
Actual Primary Completion Date :
Jul 15, 2020
Actual Study Completion Date :
Feb 5, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Problem-Solving Therapy

Participants in the intervention group receive the friendship bench intervention in addition to all services provided according to enhanced standard of care.

Behavioral: Friendship bench intervention
The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.

Other: Enhanced Standard of Care
Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.

Active Comparator: Enhanced Standard of Care

Participants in the control group receive enhanced standard of care.

Other: Enhanced Standard of Care
Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.

Outcome Measures

Primary Outcome Measures

  1. Average difference in mean antiretroviral therapy adherence between 2 and 6 months [2-6 months]

    Adherence will be calculated as percentage of prescribed doses taken and measured with the Medication Event Monitoring System (MEMS)

Secondary Outcome Measures

  1. Difference in mean antiretroviral therapy adherence between 1 and 12 months [1-12 months]

    Adherence will be calculated as percentage of prescribed doses taken and measured with the Medication Event Monitoring System (MEMS)

  2. Difference in change from baseline in Shona Symptoms Questionnaire (SSQ-14) score [At month 3, 6, 9, and 12]

    The Shone Symptoms Questionnaire is a 14 item tool. The reported total score is between 0 and 14. 14 is the highest level of mental disorder. Each item adds a score of 0 or 1 to the total score.

  3. Difference in change from baseline in Patient Health Questionnaire (PHQ-9) score [At month 3, 6, 9, and 12]

    The Patient Health Questionnaire is a 9 item tool. The reported total score is between 0 and 27. 27 is the highest level of depression. Each item adds a score of 0 to 3 to the total score.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age ≥18 years

  • Use of first-line antiretroviral therapy for at least 6 months

  • Resident in Bikita District

  • Knowledge of English or Shona language

  • Ability to comprehend the information on the study

  • Positive screening for common mental disorders (SSQ-14 score ≥9)

  • Providing informed consent

Exclusion Criteria:
  • Current psychosis / cognitive impairment

  • Clinical AIDS (WHO clinical stage 4)

  • Known pregnancy or ≤3 months postpartum

Contacts and Locations

Locations

Site City State Country Postal Code
1 Solidarmed Masvingo Zimbabwe

Sponsors and Collaborators

  • University of Bern
  • SolidarMed

Investigators

  • Principal Investigator: Andreas D Haas, PhD, Institute of Social and Preventive Medicine (ISPM), University of Bern
  • Principal Investigator: Cordelia Kunzekwenyika, MD, SolidarMed, Swiss Organisation for Health in Africa

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Bern
ClinicalTrials.gov Identifier:
NCT03704805
Other Study ID Numbers:
  • FB-ART
First Posted:
Oct 15, 2018
Last Update Posted:
Feb 15, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 15, 2022